(Q58190179)

English

Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus

article published in 2011

In more languages

Statements

scholarly article

0 references

Cerebrospinal fluid levels of a proliferation-inducing ligand (APRIL) are increased in patients with neuropsychiatric systemic lupus erythematosus (English)

0 references

neuropsychiatric systemic lupus erythematosus

0 references

object named as

M Khademi

3

0 references

Elisabet Svenungsson

object named as

E Svenungsson

6

0 references

7

object named as

M Andersson

0 references

author name string

L Hopia

1

0 references

M Thangarajh

2

0 references

A Laveskog

4

0 references

E Wallström

5

0 references

publication date

18 May 2011

0 references

Scandinavian Journal of Rheumatology

0 references

40

0 references

5

0 references

363-372

0 references

Neuropsychiatric syndromes in lupus: prevalence using standardized definitions.

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: An international inception cohort study

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

The neuropathology and pathogenesis of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Central nervous system nitric oxide formation in cerebral systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Interferon-alpha in lupus psychosis

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

A subset of lupus anti-DNA antibodies cross-reacts with the NR2 glutamate receptor in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Human lupus autoantibodies against NMDA receptors mediate cognitive impairment.

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

BAFF AND APRIL: a tutorial on B cell survival

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

BAFF, APRIL and their receptors: structure, function and signaling

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

An APRIL to remember: novel TNF ligands as therapeutic targets

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Identification of proteoglycans as the APRIL-specific binding partners.

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Raised serum APRIL levels in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Increased levels of APRIL (a proliferation-inducing ligand) mRNA in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

The 1982 revised criteria for the classification of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging.

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study.

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS?

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Raised intrathecal levels of APRIL and BAFF in patients with systemic lupus erythematosus: relationship to neuropsychiatric symptoms

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

A proliferation-inducing ligand (APRIL) is expressed by astrocytes and is increased in multiple sclerosis

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement.

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

BAFF overexpression and accelerated glomerular disease in mice with an incomplete genetic predisposition to systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Prevalence and correlates of perceived unmet needs of people with systemic lupus erythematosus.

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

On the potential role of glutamate transport in mental fatigue

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Similarities and differences between selective and nonselective BAFF blockade in murine SLE

1 reference

https://api.crossref.org/works/10.3109%2F03009742.2010.550900

21 January 2018

Identifiers

10.3109/03009742.2010.550900

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58190179&oldid=2031008676"